A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) | NCT01594970 | Trialant
CompletedInterventionalPhase 4Updated Jan 28, 2014
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
ClinicalTrials.gov ID
NCT01594970
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
800Actual
Last Update Posted
Jan 28, 2014Estimated
Start Date
Mar 2012
Primary Completion Date
Jan 2013Actual
Completion Date
Jan 2013Actual
Brief Summary
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
Glaucoma, Open-Angle
Ocular Hypertension
Bimatoprost 0.01%
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Elevated IOP due to either primary open-angle glaucoma or ocular hypertension